Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zap aftermath: can we map and avoid memory loss?

NCT ID NCT06466720

Knowledge-focused Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks 80 patients with brain tumors (metastases or meningiomas) who receive stereotactic radiosurgery. Researchers use memory tests and quality-of-life questionnaires before treatment and every 3 months for a year to see if and how brain function changes. By comparing test results with MRI scans and radiation plans, they hope to pinpoint brain regions where reducing radiation could prevent cognitive decline.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors reduce radiation to brain areas that cause thinking problems, potentially improving quality of life for future patients.
What could go wrong
This is a small pilot study, so results may not apply to all patients. It only measures changes and does not test a new treatment, so direct benefits are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The population is based within the East Midlands, United Kingdom. The East Midlands Stereotactic Radiosurgery (SRS) service covers Nottinghamshire, Derbyshire, Lincolnshire and Leicestershire. Any patients that are eligible for SRS (prospective cohort) or has already been treated with SRS (retrospective cohort) and also fulfil the eligibility criteria of the study will be invited to take part in the study. Patients will be recruited through the SRS clinics taking place at City Campus, Nottingham University Hospitals NHS Trust.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria Prospective Cohort Patients will be eligible for inclusion only if ALL of the following criteria apply: * Age: above 18 years, no upper limit * Diagnosis of brain metastases or meningioma, where the treatment is going to be stereotactic radiosurgery * Karnofsky Performance Status (KPS) ≥70 * Established diagnosis of cancer with absent or controllable primary disease * Tumour volume of less than 20cc * Life expectancy of more than 6 months * Able to give informed consent Exclusion criteria Prospective Cohort * Previous RT to the brain, including SRS * Previous surgery to the brain * Not willing or not able to give informed consent Inclusion criteria Retrospective Cohort Patients will be eligible for inclusion only if ALL of the following criteria apply: * Age: above 18 years, no upper limit * Diagnosis of meningioma * Previous SRS treatment at least 1 year prior to inclusion in the study * Most recent MRI scan (within 1 year) shows stable appearances * Able to give informed consent Exclusion criteria Retrospective Cohort * Previous RT to the brain, excluding SRS * Previous surgery to the brain * Not willing or not able to give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer Cognitive Dysfunction meningioma metastatic malignant neoplasm in the brain Silver-Russell syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases Cognitive decline Meningiomas Quality of life SRS Stereotactic radiosurgery

Contacts and locations

Locations

  • Nottingham University Hospitals NHS Trust

    Nottingham, Nottinghamshire, NG5 1 PB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.